Anti-hepatitis C Therapy and Recurrence of Hepatocellular Carcinoma After Intent-to-Cure Therapy: Meta-Analysis

2017 ◽  
Vol 112 ◽  
pp. S544-S545
Author(s):  
Michael Min ◽  
Ibrahim Hanouneh
2020 ◽  
Vol 16 (11) ◽  
pp. 675-686
Author(s):  
Longteng Ma ◽  
Jiluo Liu ◽  
Wei Wang ◽  
Fan Yang ◽  
Ping Li ◽  
...  

Aim: It was controversial whether direct-acting antiviral (DAA) is better than interferon-based therapy (IBT) in preventing HCV-related hepatocellular carcinoma (HCC). Therefore, we accomplished this large, stepwise meta-analysis. Materials & methods: The PubMed, Cochrane and ScienceDirect were searched for studies published during January 2009–March 2019. Antiviral type, number of chronic hepatitis C (CHC) patients, number of HCC cases from CHC patients, sustained virological response (SVR) status and important covariate data were extracted from each study. Results & conclusion: It is demonstrated that antiviral treatment reduces the occurrence of HCC in patients with CHC; achieving SVR to antiviral treatment reduces HCC; DAA treatment is not better than IBT in the prophylaxis of HCC; DAA treatment and cirrhosis are independently associated with a higher incidence of HCC than IBT in middle-aged CHC patients who achieve SVR.


2015 ◽  
Vol 16 (8) ◽  
pp. 19698-19712 ◽  
Author(s):  
Roberta D'Ambrosio ◽  
Cristina Della Corte ◽  
Massimo Colombo

Sign in / Sign up

Export Citation Format

Share Document